Anebulo PharmaceuticalsANEB
13F holders, Q1 2024 (March 31)15holders
$2.87avg. 13F price*
At the end of Q1 2024, 15 institutions reported holding Anebulo Pharmaceuticals Inc. (ANEB) in their 13F filings. The largest holders were 22NW, LP ($15.4M), LVW Advisors, LLC ($1.8M) and Nantahala Capital Management, LLC ($1.5M).
- Company
- Anebulo Pharmaceuticals Inc.
- CUSIP
- 034569103
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $138K |
| Exits | 3 | $39K |
Ownership 15 holders
| 22NW, LP | 13.27% | No change | 5,366,290 | $15.4M |
| LVW Advisors, LLC | 0.31% | Reduce -0.2% | 642,039 | $1.8M |
| Nantahala Capital Management, LLC | 0.14% | No change | 511,073 | $1.5M |
| Morgan Stanley | 0.00% | No change | 399,219 | $1.1M |
| Ikarian Capital, LLC | 0.12% | No change | 157,862 | $453K |
| Vanguard Group Inc. | 0.00% | Add +0.3% | 153,472 | $440K |
| Susquehanna International Group, LLP | 0.00% | New | 25,253 | $72K |
| Geode Capital Management, LLC | 0.00% | New | 22,777 | $65K |
| Boothbay Fund Management, LLC | 0.00% | No change | 18,978 | $54K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -43.5% | 5,138 | $15K |
| BlackRock Inc. | 0.00% | Reduce -2.3% | 4,049 | $12K |
| UBS Group AG | 0.00% | New | 144 | $413 |
| Wells Fargo & Company | 0.00% | Add +1.6% | 62 | $178 |
| JPMorgan Chase & Co. | 0.00% | New | 9 | $26 |
| Royal Bank of Canada | 0.00% | Reduce -46.5% | 38 | $0 |
"% of holder's portfolio" is ANEB's weight in each manager's 13F, not the share of Anebulo Pharmaceuticals Inc. the manager owns.